Gene Transfer Establishes Primacy of Striated Vs. Smooth Muscle Sarcoglycan Complex in Limb-Girdle Muscular Dystrophy

Total Page:16

File Type:pdf, Size:1020Kb

Gene Transfer Establishes Primacy of Striated Vs. Smooth Muscle Sarcoglycan Complex in Limb-Girdle Muscular Dystrophy Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy Madeleine Durbeej*, Shanna M. Sawatzki*, Rita Barresi*, Kathleen M. Schmainda†, Vale´ rie Allamand*, Daniel E. Michele*, and Kevin P. Campbell*‡ *Howard Hughes Medical Institute, Department of Physiology and Biophysics, Department of Neurology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242-1101; and †Department of Radiology and Biophysics Research Institute, Medical College of Wisconsin, Milwaukee, WI 53226 Edited by Gerald D. Fischbach, Columbia University College of Physicians and Surgeons, New York, NY, and approved May 19, 2003 (received for review December 16, 2002) Limb-girdle muscular dystrophy types 2E and F are characterized by muscle, ␣-SG deficiency does not lead to cardiomyopathy. Also, skeletal muscle weakness and often cardiomyopathy and are due the dystrophic phenotype appears less severe in ␣-SG-deficient to mutations in the genes encoding ␤- and ␦-sarcoglycan. We mice compared to the muscular dystrophy that develops in ␤- and previously demonstrated that loss of sarcoglycans in smooth mus- ␦-SG-deficient mice. Mice lacking ␤- and ␦-SG display large cle leads to constrictions of the microvasculature that contributes areas of necrosis as the predominant characteristic feature to the cardiac phenotype. It is unclear how vasculature abnormal- similar to alterations observed in tissue infarcts. In addition, ities affect skeletal muscle. We injected recombinant ␤-or␦- arterial constrictions are detected in skeletal muscle (11, 12). sarcoglycan adenoviruses into skeletal muscles of corresponding Despite uniform gene disruption, the surprising heterogeneity of null mice. We hypothesized that the adenoviruses would not phenotype within muscle groups, such as these focal regions of transduce vascular smooth muscle, and we would only target necrosis surrounded by regions of near normalcy, suggests the skeletal muscle. Indeed, sustained expression of intact sarcoglycan– possibility that vascular abnormalities are playing a primary role sarcospan complex was noted at the sarcolemma, neuromuscular in these muscular dystrophies. However, the hypothesis that junction, myotendinous junction, and in peripheral nerve, but not vascular dysfunction directly initiates muscular dystrophy has in vascular smooth muscle. Gene transfer of the corresponding remained untested (11, 12). To address this question, we injected deleted sarcoglycan gene preserved sarcolemmal integrity, pre- recombinant ␤-or␦-SG adenoviruses into corresponding null vented pathological dystrophy and hypertrophy, and protected mice (Sgcb- or Sgcd-null, respectively). We hypothesized that the against exercised-induced damage. We conclude that vascular adenoviruses would not cross the perimysium, in which blood ␤ ␦ dysfunction is not a primary cause of - and -sarcoglycan-defi- vessels run, and thus we would only target skeletal muscle. The cient muscular dystrophy. In addition, we show successful func- sarcoglycans were successfully restored at the sarcolemma, neu- tional rescue of entire muscles after adenovirus-mediated gene romuscular junction (NMJ), myotendinous junction (MTJ), and delivery. Thus, virus-mediated gene transfer of sarcoglycans to peripheral nerve, but not in smooth muscle of vessels within the skeletal muscle in combination with pharmacological prevention of skeletal muscle. Despite lack of restoration in vascular smooth cardiomyopathy constitute promising therapeutic strategies for muscle, the dystrophic phenotype was prevented, as demon- limb-girdle muscular dystrophies. strated by improved skeletal muscle morphology, restored sar- colemmal integrity, and reduction of muscle mass. Also, injec- he sarcoglycans (␣, ␤, ␥, and ␦-SG) are localized at the tion of ␦-SG adenovirus was able to prevent the development of Tsarcolemma of muscle fibers and form, along with sarcospan, exercise-induced injury. We conclude that (i) disruption of the a subcomplex within the larger dystrophin–glycoprotein com- DGC in vascular smooth muscle is not a primary cause of plex (DGC) (1–3). The DGC is further composed of the muscular dystrophy; (ii) primary mutations in ␤- and ␦-SG can intracellularly located protein dystrophin, which binds to the be functionally corrected in vivo; and (iii) structures such as ␤ transmembrane protein -dystroglycan, which is associated with NMJ, MTJ, and peripheral nerve that are affected in muscular ␣ ␣ the peripheral protein -dystroglycan. -Dystroglycan, in turn, dystrophy and other neuromuscular diseases can be targets for binds to laminin-2, present in the skeletal muscle basement adenoviral-mediated gene delivery. membrane (4, 5). Thus, the DGC provides a structural link between the extracellular matrix and the intracellular cytoskel- Methods eton of muscle cells. The importance of the sarcoglycans for Animals. We previously reported the generation of Sgcb-null normal skeletal muscle function is underscored by the findings ␥ ␣ ␤ ␦ mice, lines Q94 and Q283 (12). Here, we have also analyzed that mutations in the genes for -, -, -, and -SG cause Sgcb-null mice from a third clone, Q201. Sgcd-null mice, line I74 limb-girdle muscular dystrophy types 2C-F, respectively. Fur- were also described (11). All mice were on hybrid C57BL͞6– thermore, one mutant sarcoglycan isoform causes the loss or the 129-SvJ background. Colonies were maintained in the Animal reduction at the muscle cell membrane of all of the other Care Unit of the University of Iowa College of Medicine, sarcoglycan proteins in the DGC (6). according to the animal care guidelines. The Animal Care and In striated muscle, the sarcoglycan complex is composed of ␣-, Use Review Committees of the University of Iowa and the ␤-, ␥-, and ␦-SG. In addition, a second sarcoglycan complex in Medical College of Wisconsin approved all animal procedures. which ␧-SG replaces ␣-SG is also expressed in striated muscle and is predominant in smooth muscle (7–10). Loss of the sarcoglycans in vascular smooth muscle results in perturbed This paper was submitted directly (Track II) to the PNAS office. vascular function with the presence of vascular constrictions Abbreviations: SG, sarcoglycan; DGC, dystrophin–glycoprotein complex; NMJ, neuromus- leading to intermittent ischemic-like events, which initiate the cular junction; MTJ, myotendinous junction; EBD, Evans blue dye; nNOS, neuronal nitric development of cardiomyopathy in mouse models of ␤- and ␦-SG oxide synthase. deficiency (11–13). Because ␣-SG is not expressed in smooth ‡To whom correspondence should be addressed. E-mail: [email protected]. 8910–8915 ͉ PNAS ͉ July 22, 2003 ͉ vol. 100 ͉ no. 15 www.pnas.org͞cgi͞doi͞10.1073͞pnas.1537554100 Downloaded by guest on September 26, 2021 Recombinant Adenoviral Vectors. Human ␤- and ␦-SG sequences were amplified by PCR and subcloned into the pAdCMVpA adenovirus shuttle vector. The ␤- and ␦-SG constructs were then incorporated into an adenovirus vector through standard meth- ods of homologous recombination with Ad5 backbone dl309 by the University of Iowa Gene Transfer Vector Core. First- generation recombinant viruses were purified as described (12, 14). Adenoviral Vector Administration. Sgcb- and Sgcd-null pups (2- to 4-day-old) were anesthetized via hypothermia by placement on ice-cooled aluminum foil for 1–2 min. Infectious particles (1–2 ϫ 109) of Ad5 cytomegalovirus containing human ␤-or␦-SG cDNA diluted in a final volume of 10 ␮l in 0.9% NaCl were injected percutaneously into each skeletal muscle of the corre- sponding null mice by using an insulin syringe. Pups were reintroduced to the mother and kept in quarantine for 5 days. All pups survived after injections. Immunohistochemical Analysis. Stainings were performed as de- scribed (12) with Abs against ␤-dystroglycan (15); ␣-, ␤-, ␥-, and ␦-SG (8, 14, 16, 17); sarcospan (18), and neuronal nitric oxide synthase (nNOS) (19). The smooth muscle actin Ab was from Sigma. Secondary Abs were conjugated with FITC or Cy3 (Jackson ImmunoResearch) or Alexa Fluor 488 (Molecular Probes). For staining of NMJs, samples were simultaneously incubated with FITC-conjugated ␣-bungarotoxin (Molecular Probes). Sections were observed under an MRC-600 laser scanning confocal microscope (Bio-Rad) or a Leica DMRXA MEDICAL SCIENCES fluorescence microscope (Leica, Deerfield, IL). Biochemical Analysis. Glycoprotein preparations were performed as described (12) and analyzed by using Abs against ␣-SG (␣Sarc͞20A6); ␤-SG (␤Sarc͞5B1); ␣-dystroglycan (IIH6) (20); ␣2 subunit of the dihydropyridine receptor (21); ␦-SG (14) and sarcospan (18). MRI. Before imaging, mice were anesthetized with 87.5 mg͞kg ketamine and 12.5 mg͞kg xylazine and surgically instrumented Fig. 1. Restoration of the sarcoglycan–sarcospan complex and nNOS at the with vein catheters for the administration of gadolinium (Ga- sarcolemma upon adenovirus-mediated expression of ␤- and ␦-SG. (a) Quad- dodiamide, Omniscan; Nycomed, Oslo). All experiments were riceps muscle cryosections from WT, Sgcb-null, Sgcb-null mice injected with performed at the Medical College of Wisconsin on a 3-T Bruker recombinant ␤-SG adenovirus, Sgcd-null, and Sgcd-null mice injected with Medspec MR imaging system (Bruker, Billerica, MA). Mice recombinant ␦-SG adenovirus were stained with Abs against ␣-SG, ␤-SG, ␥-SG, ␦ were placed in a 10-cm three-axis local gradient coil, together -SG, sarcospan (SSPN), and nNOS. (b) Glycoprotein preparations from quad- ϫ ͞ riceps muscle
Recommended publications
  • Tibialis Posterior Tendon Transfer Corrects the Foot Drop Component
    456 COPYRIGHT Ó 2014 BY THE JOURNAL OF BONE AND JOINT SURGERY,INCORPORATED Tibialis Posterior Tendon Transfer Corrects the Foot DropComponentofCavovarusFootDeformity in Charcot-Marie-Tooth Disease T. Dreher, MD, S.I. Wolf, PhD, D. Heitzmann, MSc, C. Fremd, M.C. Klotz, MD, and W. Wenz, MD Investigation performed at the Division for Paediatric Orthopaedics and Foot Surgery, Department for Orthopaedic and Trauma Surgery, Heidelberg University Clinics, Heidelberg, Germany Background: The foot drop component of cavovarus foot deformity in patients with Charcot-Marie-Tooth disease is commonly treated by tendon transfer to provide substitute foot dorsiflexion or by tenodesis to prevent the foot from dropping. Our goals were to use three-dimensional foot analysis to evaluate the outcome of tibialis posterior tendon transfer to the dorsum of the foot and to investigate whether the transfer works as an active substitution or as a tenodesis. Methods: We prospectively studied fourteen patients with Charcot-Marie-Tooth disease and cavovarus foot deformity in whom twenty-three feet were treated with tibialis posterior tendon transfer to correct the foot drop component as part of a foot deformity correction procedure. Five patients underwent unilateral treatment and nine underwent bilateral treatment; only one foot was analyzed in each of the latter patients. Standardized clinical examinations and three-dimensional gait analysis with a special foot model (Heidelberg Foot Measurement Method) were performed before and at a mean of 28.8 months after surgery. Results: The three-dimensional gait analysis revealed significant increases in tibiotalar and foot-tibia dorsiflexion during the swing phase after surgery. These increases were accompanied by a significant reduction in maximum plantar flexion at the stance-swing transition but without a reduction in active range of motion.
    [Show full text]
  • 2.04.132 Genetic Testing for Limb-Girdle Muscular Dystrophies
    Medical Policy MP 2.04.132 Genetic Testing for Limb-Girdle Muscular Dystrophies BCBSA Ref. Policy: 2.04.132 Related Policies Last Review: 05/27/2021 2.04.86 Genetic Testing for Duchenne and Becker Effective Date: 05/27/2021 Muscular Dystrophy Section: Medicine 2.04.105 Genetic Testing for Facioscapulohumeral Muscular Dystrophy 2.04.570 Genetic Counseling DISCLAIMER/INSTRUCTIONS FOR USE Medical policy provides general guidance for applying Blue Cross of Idaho benefit plans (for purposes of medical policy, the terms “benefit plan” and “member contract” are used interchangeably). Coverage decisions must reference the member specific benefit plan document. The terms of the member specific benefit plan document may be different than the standard benefit plan upon which this medical policy is based. If there is a conflict between a member specific benefit plan and the Blue Cross of Idaho’s standard benefit plan, the member specific benefit plan supersedes this medical policy. Any person applying this medical policy must identify member eligibility, the member specific benefit plan, and any related policies or guidelines prior to applying this medical policy, including the existence of any state or federal guidance that may be specific to a line of business. Blue Cross of Idaho medical policies are designed for informational purposes only and are not an authorization, explanation of benefits or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the member specific benefit plan coverage. Blue Cross of Idaho reserves the sole discretionary right to modify all its policies and guidelines at any time.
    [Show full text]
  • Chronic Tibialis Anterior Tendon Tear Treated with an Achilles Tendon Allograft Technique
    n tips & techniques Section Editor: Steven F. Harwin, MD Chronic Tibialis Anterior Tendon Tear Treated With an Achilles Tendon Allograft Technique Ezequiel Palmanovich, MD; Yaron S. Brin, MD; Lior Laver, MD; Dror Ben David, MD; Sabri Massrawe, MD; Meir Nyska, MD; Iftach Hetsroni, MD tus,16,17 rheumatoid arthritis,17 erative tibialis anterior tendon Abstract: Tibialis anterior tendon tear is an uncommon in- psoriasis,18 and deposition of was diagnosed clinically and jury. Nontraumatic or degenerative tears are usually seen gout tophi19,20 also have been confirmed by ultrasound. in the avascular zone of the tendon. Treatment can be con- reported to be associated with After 3 months of phys- servative or surgical. Conservative treatment is adequate tendon ruptures. In older pa- iotherapy treatment without for low-demand older patients. For active patients, surgical tients and in partial tears, non- improvement, surgical treat- treatment can be challenging for the surgeon because after operative treatment has been ment was recommended. The debridement of degenerative tissue, a gap may be formed described.8,21 patient’s American Orthopae- that can make side-to-side suture impossible. The authors Surgical techniques de- dic Foot and Ankle Society present allograft Achilles tendon insertion for reconstruc- scribed in the literature in- (AOFAS)22 score was 23 and tion of chronic degenerative tears. Using Achilles tendon al- clude direct side-to-side his Foot and Ankle Disabil- lograft has the advantage of bone-to-bone fixation, allowing repair and interposition of ity Index (FADI)23 score was rapid incorporation and earlier full weight bearing. autogenous tendon graft for 34.6 preoperatively.
    [Show full text]
  • Development of a High-Throughput Screen to Identify Small Molecule Enhancers of Sarcospan for the Treatment of Duchenne Muscular Dystrophy
    UCLA UCLA Previously Published Works Title Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy. Permalink https://escholarship.org/uc/item/85z6k8t7 Journal Skeletal muscle, 9(1) ISSN 2044-5040 Authors Shu, Cynthia Kaxon-Rupp, Ariana N Collado, Judd R et al. Publication Date 2019-12-12 DOI 10.1186/s13395-019-0218-x Peer reviewed eScholarship.org Powered by the California Digital Library University of California Shu et al. Skeletal Muscle (2019) 9:32 https://doi.org/10.1186/s13395-019-0218-x RESEARCH Open Access Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy Cynthia Shu1,2,3, Ariana N. Kaxon-Rupp2, Judd R. Collado2, Robert Damoiseaux4,5 and Rachelle H. Crosbie1,2,3,6* Abstract Background: Duchenne muscular dystrophy (DMD) is caused by loss of sarcolemma connection to the extracellular matrix. Transgenic overexpression of the transmembrane protein sarcospan (SSPN) in the DMD mdx mouse model significantly reduces disease pathology by restoring membrane adhesion. Identifying SSPN-based therapies has the potential to benefit patients with DMD and other forms of muscular dystrophies caused by deficits in muscle cell adhesion. Methods: Standard cloning methods were used to generate C2C12 myoblasts stably transfected with a fluorescence reporter for human SSPN promoter activity. Assay development and screening were performed in a core facility using liquid handlers and imaging systems specialized for use with a 384-well microplate format. Drug-treated cells were analyzed for target gene expression using quantitative PCR and target protein expression using immunoblotting.
    [Show full text]
  • Beta Sarcoglycan (SGCB) (NM 000232) Human Untagged Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC120022 beta Sarcoglycan (SGCB) (NM_000232) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: beta Sarcoglycan (SGCB) (NM_000232) Human Untagged Clone Tag: Tag Free Symbol: SGCB Synonyms: A3b; LGMD2E; LGMDR4; SGC Vector: pCMV6-XL5 E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: None Fully Sequenced ORF: >NCBI ORF sequence for NM_000232, the custom clone sequence may differ by one or more nucleotides ATGGCGGCAGCGGCGGCGGCGGCTGCAGAACAGCAAAGTTCCAATGGTCCTGTAAAGAAGTCCATGCGTG AGAAGGCTGTTGAGAGAAGGAGTGTCAATAAAGAGCACAACAGTAACTTTAAAGCTGGATACATTCCGAT TGATGAAGATCGTCTCCACAAAACAGGGTTGAGAGGAAGAAAGGGCAATTTAGCCATCTGTGTGATTATC CTCTTGTTTATCCTGGCTGTCATCAATTTAATAATAACACTTGTTATTTGGGCCGTGATTCGCATTGGAC CAAATGGCTGTGATAGTATGGAGTTTCATGAAAGTGGCCTGCTTCGATTTAAGCAAGTATCTGACATGGG AGTGATCCACCCTCTTTATAAAAGCACAGTAGGAGGAAGGCGAAATGAAAATTTGGTCATCACTGGCAAC AACCAGCCTATTGTTTTTCAGCAAGGGACAACAAAGCTCAGTGTAGAAAACAACAAAACTTCTATTACAA GTGACATCGGCATGCAGTTTTTTGACCCGAGGACTCAAAATATCTTATTCAGCACAGACTATGAAACTCA TGAGTTTCATTTGCCAAGTGGAGTGAAAAGTTTGAATGTTCAAAAGGCATCTACTGAAAGGATTACCAGC AATGCTACCAGTGATTTAAATATAAAAGTTGATGGGCGTGCTATTGTGCGTGGAAATGAAGGTGTATTCA TTATGGGCAAAACCATTGAATTTCACATGGGTGGTAATATGGAGTTAAAGGCGGAAAACAGTATCATCCT AAATGGATCTGTGATGGTCAGCACCACCCGCCTACCCAGTTCCTCCAGTGGAGACCAGTTGGGTAGTGGT GACTGGGTACGCTACAAGCTCTGCATGTGTGCTGATGGGACGCTCTTCAAGGTGCAAGTAACCAGCCAGA
    [Show full text]
  • Altered Ca2+ Handling and Oxidative Stress Underlie Mitochondrial Damage and Skeletal Muscle Dysfunction in Aging and Disease
    H OH metabolites OH Review Altered Ca2+ Handling and Oxidative Stress Underlie Mitochondrial Damage and Skeletal Muscle Dysfunction in Aging and Disease Antonio Michelucci 1,*, Chen Liang 2 , Feliciano Protasi 3 and Robert T. Dirksen 2 1 DNICS, Department of Neuroscience, Imaging, and Clinical Sciences, University G. d’Annunzio of Chieti-Pescara, I-66100 Chieti, Italy 2 Department of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642, USA; [email protected] (C.L.); [email protected] (R.T.D.) 3 CAST, Center for Advanced Studies and Technology, DMSI, Department of Medicine and Aging Sciences, University G. d’Annunzio of Chieti-Pescara, I-66100 Chieti, Italy; [email protected] * Correspondence: [email protected] Abstract: Skeletal muscle contraction relies on both high-fidelity calcium (Ca2+) signals and robust capacity for adenosine triphosphate (ATP) generation. Ca2+ release units (CRUs) are highly organized junctions between the terminal cisternae of the sarcoplasmic reticulum (SR) and the transverse tubule (T-tubule). CRUs provide the structural framework for rapid elevations in myoplasmic Ca2+ during excitation–contraction (EC) coupling, the process whereby depolarization of the T-tubule membrane triggers SR Ca2+ release through ryanodine receptor-1 (RyR1) channels. Under conditions of local Citation: Michelucci, A.; Liang, C.; or global depletion of SR Ca2+ stores, store-operated Ca2+ entry (SOCE) provides an additional 2+ Protasi, F.; Dirksen, R.T. Altered Ca source of Ca2+ that originates from the extracellular space. In addition to Ca2+, skeletal muscle also Handling and Oxidative Stress requires ATP to both produce force and to replenish SR Ca2+ stores.
    [Show full text]
  • Treatment of Spastic Foot Deformities
    TREATMENT OF SPASTIC FOOT DEFORMITIES penn neuro-orthopaedics service Table of Contents OVERVIEW Severe loss of movement is often the result of neurological disorders, Overview .............................................................. 1 such as stroke or brain injury. As a result, ordinary daily activities Treatment ............................................................. 2 such as walking, eating and dressing can be difficult and sometimes impossible to accomplish. Procedures ........................................................... 4 The Penn Neuro-Orthopaedics Service assists patients with Achilles Tendon Lengthening .........................................4 orthopaedic problems caused by certain neurologic disorders. Our Toe Flexor Releases .....................................................5 team successfully treats a wide range of problems affecting the limbs including foot deformities and walking problems due to abnormal Toe Flexor Transfer .......................................................6 postures of the foot. Split Anterior Tibialis Tendon Transfer (SPLATT) ...............7 This booklet focuses on the treatment of spastic foot deformities The Extensor Tendon of the Big Toe (EHL) .......................8 under the supervision of Keith Baldwin, MD, MSPT, MPH. Lengthening the Tibialis Posterior Tendon .......................9 Care After Surgery .................................................10 Notes ..................................................................12 Pre-operative right foot. Post-operative
    [Show full text]
  • Limb-Girdle Muscular Dystrophy
    www.ChildLab.com 800-934-6575 LIMB-GIRDLE MUSCULAR DYSTROPHY What is Limb-Girdle Muscular Dystrophy? Limb-Girdle Muscular Dystrophy (LGMD) is a group of hereditary disorders that cause progressive muscle weakness and wasting of the shoulders and pelvis (hips). There are at least 13 different genes that cause LGMD, each associated with a different subtype. Depending on the subtype of LGMD, the age of onset is variable (childhood, adolescence, or early adulthood) and can affect other muscles of the body. Many persons with LGMD eventually need the assistance of a wheelchair, and currently there is no cure. How is LGMD inherited? LGMD can be inherited by autosomal dominant (AD) or autosomal recessive (AR) modes. The AR subtypes are much more common than the AD types. Of the AR subtypes, LGMD2A (calpain-3) is the most common (30% of cases). LGMD2B (dysferlin) accounts for 20% of cases and the sarcoglycans (LGMD2C-2F) as a group comprise 25%-30% of cases. The various subtypes represent the different protein deficiencies that can cause LGMD. What testing is available for LGMD? Diagnosis of the LGMD subtypes requires biochemical and genetic testing. This information is critical, given that management of the disease is tailored to each individual and each specific subtype. Establishing the specific LGMD subtype is also important for determining inheritance and recurrence risks for the family. The first step in diagnosis for muscular dystrophy is usually a muscle biopsy. Microscopic and protein analysis of the biopsy can often predict the type of muscular dystrophy by analyzing which protein(s) is absent. A muscle biopsy will allow for targeted analysis of the appropriate LGMD gene(s) and can rule out the diagnosis of the more common dystrophinopathies (Duchenne and Becker muscular dystrophies).
    [Show full text]
  • Traumatic Tear of Tibialis Anterior During a Gaelic Football Game: a Case Report M Constantinou, a Wilson
    1of3 Br J Sports Med: first published as 10.1136/bjsm.2003.007625 on 23 November 2004. Downloaded from CASE REPORT Traumatic tear of tibialis anterior during a Gaelic football game: a case report M Constantinou, A Wilson ............................................................................................................................... Br J Sports Med 2004;38:e30 (http://www.bjsportmed.com/cgi/content/full/38/6/e30) were considered irrefutable evidence of a rupture, so Reports of traumatic injury to the anterior lower leg muscles operative management was undertaken one week after the are scarce, with only a handful of reports of traumatic injury injury. to the tibialis anterior. A database search of Medline, Cinhal, Surgery revealed a complete traumatic tear of tibialis and Sports Discus only revealed three such cases, and they anterior at the musculotendinous junction. The tendon had did not result from a direct sporting injury. This report ruptured directly from the muscle belly, which had also documents the case of a traumatic rupture of tibialis anterior sustained some muscle fibre damage (fig 1). The tendon was muscle in a young female Gaelic football player. It details the subsequently sutured back to the muscle belly using surgical repair and management of tibialis anterior muscle absorbable interrupted sutures. and the physiotherapy rehabilitation to full function. Post-surgical management consisted of an initial period of six weeks non-weight bearing and immobilisation in a short leg fibreglass cast, followed by four weeks in an ankle-foot orthosis with partial weight bearing. Active physiotherapy raumatic injuries to the lower limb are often associated rehabilitation was begun 10 weeks after surgery. The with contact team sports.
    [Show full text]
  • Axis Scientific 9-Part Foot with Muscles, Ligaments, Nerves & Arteries A-105857
    Axis Scientific 9-Part Foot with Muscles, Ligaments, Nerves & Arteries A-105857 DORSAL VIEW LATERAL VIEW 53. Superficial Fibular (Peroneal) Nerve 71. Fibula 13. Fibularis (Peroneus) Longus Tendon 17. Anterior Talofibular Ligament 09. Fibularis (Peroneus) 72. Lateral Malleolus Tertius Tendon 21. Kager’s Fat Pad 07. Superior Extensor 15. Superior Fibular Retinaculum (Peroneal) Retinaculum 51. Deep Fibular Nerve 52. Anterior Tibial Artery 19. Calcaneal (Achilles) Tendon 16. Inferior Fibular 02. Tibialis Anterior Tendon (Peroneal) Retinaculum 42. Intermedial Dorsal 08. Inferior Extensor 73. Calcaneus Bone Cutaneous Nerve Retinaculum 43. Lateral Dorsal Cutaneous Nerve 44. Dorsalis Pedis Artery 11. Extensor Digitorum 32. Abductor Digiti Minimi Muscle Brevis Muscle 04. Extensor Hallucis Longus Tendon 48. Medial Tarsal Artery 06. Extensor Digitorum 10. Extensor Hallucis Longus Tendons Brevis Muscle 41. Medial Dorsal Cutaneous Nerve 49. Dorsal Metatarsal Artery 45. Deep Fibular (Peroneal) Nerve MEDIAL VIEW 22. Flexor Digitorum 46. Arcuate Artery Longus Muscle 68. Tibia 12. Dorsal Interossei Muscle 21. Kager’s Fat Pad 48. Medial Tarsal Artery 69. Medial Malleolus 27. Tibialis Posterior 81. Nail Tendon 18. Flexor Retinaculum 29. Abductor Hallucis Muscle 36. Flexor Muscle POSTERIOR VIEW PLANTAR VIEW 01. Tibialis Anterior Muscle 03. Extensor Hallucis 70. Interosseous Longus Muscle Membrane 23. Flexor Digitorum 05. Extensor Digitorum Longus Tendons Longus Muscle 26. Tibialis Posterior Muscle 14. Fibularis (Peroneus) 20. Soleus Muscle Brevis Muscle 24. Flexor Hallucis Longus Muscle 25. Flexor Hallucis Longus Tendon 67. Proper Plantar 66. Proper Plantar Digital Artery Digital Nerve 65. Proper Plantar Digital Nerve 80. Sesamoid Bone 31. Flexor Digitorum Brevis Tendons 19. Calcaneal (Achilles) Tendon 36. Flexor Muscle 29.
    [Show full text]
  • Dystrophin Complex Functions As a Scaffold for Signalling Proteins☆
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1838 (2014) 635–642 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamem Review Dystrophin complex functions as a scaffold for signalling proteins☆ Bruno Constantin IPBC, CNRS/Université de Poitiers, FRE 3511, 1 rue Georges Bonnet, PBS, 86022 Poitiers, France article info abstract Article history: Dystrophin is a 427 kDa sub-membrane cytoskeletal protein, associated with the inner surface membrane and Received 27 May 2013 incorporated in a large macromolecular complex of proteins, the dystrophin-associated protein complex Received in revised form 22 August 2013 (DAPC). In addition to dystrophin the DAPC is composed of dystroglycans, sarcoglycans, sarcospan, dystrobrevins Accepted 28 August 2013 and syntrophin. This complex is thought to play a structural role in ensuring membrane stability and force trans- Available online 7 September 2013 duction during muscle contraction. The multiple binding sites and domains present in the DAPC confer the scaf- fold of various signalling and channel proteins, which may implicate the DAPC in regulation of signalling Keywords: Dystrophin-associated protein complex (DAPC) processes. The DAPC is thought for instance to anchor a variety of signalling molecules near their sites of action. syntrophin The dystroglycan complex may participate in the transduction of extracellular-mediated signals to the muscle Sodium channel cytoskeleton, and β-dystroglycan was shown to be involved in MAPK and Rac1 small GTPase signalling. More TRPC channel generally, dystroglycan is view as a cell surface receptor for extracellular matrix proteins.
    [Show full text]
  • Dystrobrevin Alpha Gene Is a Direct Target of the Vitamin D Receptor in Muscle
    64 3 Journal of Molecular M K Tsoumpra et al. Upregulation of dystrobrevin by 64:3 195–208 Endocrinology calcitriol RESEARCH Dystrobrevin alpha gene is a direct target of the vitamin D receptor in muscle Maria K Tsoumpra1, Shun Sawatsubashi2, Michihiro Imamura1, Seiji Fukumoto2, Shin’ichi Takeda1, Toshio Matsumoto2 and Yoshitsugu Aoki1 1Department of Molecular Therapy, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, Tokyo, Japan 2Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan Correspondence should be addressed to S Fukumoto: [email protected] Abstract The biologically active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (VD3), exerts its Key Words tissue-specific actions through binding to its intracellular vitamin D receptor (VDR) which f vitamin D functions as a heterodimer with retinoid X receptor (RXR) to recognize vitamin D response f muscle elements (VDRE) and activate target genes. Upregulation of VDR in murine skeletal muscle f gene regulation cells occurs concomitantly with transcriptional regulation of key myogenic factors upon f receptor binding VD3 administration, reinforcing the notion that VD3 exerts beneficial effects on muscle. Herein we elucidated the regulatory role of VD3/VDR axis on the expression of dystrobrevin alpha (DTNA), a member of dystrophin-associated protein complex (DAPC). In C2C12 cells, Dtna and VDR gene and protein expression were upregulated by 1–50 nM of VD3 during all stages of myogenic differentiation. In the dystrophic-derived H2K-mdx52 cells, upregulation of DTNA by VD3 occurred upon co-transfection of VDR and RXR expression vectors. Silencing of MyoD1, an E-box binding myogenic transcription factor, did not alter the VD3-mediated Dtna induction, but Vdr silencing abolished this effect.
    [Show full text]